- Home
- PMAX vs CALC Comparison
PMAX vs CALC Comparison
Compare PMAX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- CALC
- Stock Information
- Founded
- PMAX 2019
- CALC 2011
- Country
- PMAX Hong Kong
- CALC United States
- Employees
- PMAX N/A
- CALC N/A
- Industry
- PMAX
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- CALC Health Care
- Exchange
- PMAX Nasdaq
- CALC Nasdaq
- Market Cap
- PMAX 7.9M
- CALC 22.9M
- IPO Year
- PMAX 2024
- CALC N/A
- Fundamental
- Price
- PMAX $0.50
- CALC $1.61
- Analyst Decision
- PMAX
- CALC Strong Buy
- Analyst Count
- PMAX 0
- CALC 3
- Target Price
- PMAX N/A
- CALC $16.33
- AVG Volume (30 Days)
- PMAX 1.5M
- CALC 30.2K
- Earning Date
- PMAX 04-28-2025
- CALC 08-11-2025
- Dividend Yield
- PMAX N/A
- CALC N/A
- EPS Growth
- PMAX N/A
- CALC N/A
- EPS
- PMAX N/A
- CALC N/A
- Revenue
- PMAX $4,694,079.00
- CALC N/A
- Revenue This Year
- PMAX N/A
- CALC N/A
- Revenue Next Year
- PMAX N/A
- CALC N/A
- P/E Ratio
- PMAX N/A
- CALC N/A
- Revenue Growth
- PMAX N/A
- CALC N/A
- 52 Week Low
- PMAX $0.28
- CALC $1.42
- 52 Week High
- PMAX $4.70
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- CALC 47.03
- Support Level
- PMAX N/A
- CALC $1.42
- Resistance Level
- PMAX N/A
- CALC $1.85
- Average True Range (ATR)
- PMAX 0.00
- CALC 0.15
- MACD
- PMAX 0.00
- CALC -0.00
- Stochastic Oscillator
- PMAX 0.00
- CALC 44.19
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.